Contact Us
Drug Search Results
More Filters [+]

Pacritinib

Alternative Names: pacritinib, sb1518, Vonjo
Latest Update: 2024-09-02
Latest Update Note: Clinical Trial Update

Product Description

VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 109/L. (Sourced from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5ab444-0e1a-4984-99db-76ad11a298ee)

Mechanisms of Action: JAK2 Inhibitor,IRAK1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Accelerated Approval - Myelofibrosis|Thrombocytopenia *

Approval Status: Approved

Approved Countries: United States

Approved Indications: Myelofibrosis | Polycythemia | Thrombocythemia, Essential | Polycythemia Vera

Known Adverse Events: Anemia | Thrombocytopenia | Diarrhea | Edema

Company: CTI BioPharma
Company Location: SEATTLE WA 98121
Company CEO: Adam R. Craig
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pacritinib

Countries in Clinic: Australia, Belarus, Belgium, Bosnia, Bulgaria, Canada, Czech Republic, France, Georgia, Germany, Hungary, India, Israel, Italy, Korea, Netherlands, Poland, Romania, Russia, Serbia, Spain, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential|Thrombocytopenia|Thrombocytosis

Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Graft vs Host Disease|Juvenile Myelomonocytic Leukemia,

Phase 1: Healthy Volunteers|Hepatic Insufficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
24-x213

P1

Not yet recruiting

Myelofibrosis|Thrombocytopenia

2026-11-30

HOVON 134 MF

P2

Active, not recruiting

Myelofibrosis|Polycythemia Vera|Thrombocytosis

2026-02-18

PACIFICA

P3

Active, not recruiting

Myelofibrosis|Thrombocythemia, Essential|Thrombocytopenia

2025-10-06

GCO 23-1514

P2

Recruiting

Acute Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myelomonocytic Leukemia|Acute Monocytic Leukemia

2025-07-01

Recent News Events

Date

Type

Title

07/03/2024

News Article

 DRI Healthcare Trust to Host Second Quarter Earnings Call and Webcast on August 7, 2024

07/02/2024

News Article

 DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency

05/28/2024

News Article

 BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

05/24/2024

News Article

 Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions